In COVID-19, tocilizumab reduces all-cause mortality at 28 d

被引：3
|
作者：
Fernando, Shannon M. [1 ]
Rochwerg, Bram [2 ]
机构：
[1] Univ Ottawa, Ottawa, ON, Canada
[2] McMaster Univ, Hamilton, ON, Canada
来源：
ANNALS OF INTERNAL MEDICINE | 2021年 / 174卷 / 06期
关键词：
D O I：
10.7326/ACPJ202106150-063
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：JC63 / JC63
页数：1
相关论文
共 50 条
  • [1] In patients hospitalized for COVID-19, tocilizumab reduces mortality at 28 d
    Lo, Carson K. L.
    Chagla, Zain
    [J]. ANNALS OF INTERNAL MEDICINE, 2021, 174 (11) : JC125 - JC125
  • [2] All-cause and COVID-19 mortality in Qatar during the COVID-19 pandemic
    AlNuaimi, Asma A.
    Chemaitelly, Hiam
    Semaan, Sandy
    AlMukdad, Sawsan
    Al-Kanaani, Zaina
    Kaleeckal, Anvar Hassan
    Latif, Ali Nizar
    Al-Romaihi, Hamad Eid
    Butt, Adeel A.
    Al-Thani, Mohamed H.
    Bertollini, Roberto
    AbdulMalik, Mariam
    Al-Khal, Abdullatif
    Abu-Raddad, Laith J.
    [J]. BMJ GLOBAL HEALTH, 2023, 8 (05):
  • [3] Association between tocilizumab, sarilumab and all-cause mortality at 28 days in hospitalised patients with COVID-19: A network meta-analysis
    Godolphin, Peter J.
    Fisher, David J.
    Berry, Lindsay R.
    Derde, Lennie P. G.
    Diaz, Janet, V
    Gordon, Anthony C.
    Lorenzi, Elizabeth
    Marshall, John C.
    Murthy, Srinivas
    Shankar-Hari, Manu
    Sterne, Jonathan A. C.
    Tierney, Jayne F.
    Vale, Claire L.
    [J]. PLOS ONE, 2022, 17 (07):
  • [4] Association between tocilizumab, sarilumab and all-cause mortality at 28 days in hospitalised patients with COVID-19: A network meta-analysis
    Godolphin, Peter J.
    Fisher, David J.
    Berry, Lindsay R.
    Derde, Lennie P. G.
    Diaz, Janet V.
    Gordon, Anthony C.
    Lorenzi, Elizabeth
    Marshall, John C.
    Murthy, Srinivas
    Shankar-Hari, Manu
    Sterne, Jonathan A. C.
    Tierney, Jayne F.
    Vale, Claire L.
    [J]. PLOS ONE, 2022, 17 (05):
  • [5] All-cause mortality during the COVID-19 pandemic in Peru
    Liu, Yanwen
    Zhao, Shi
    Yang, Lin
    Aliaga-Linares, Lissette
    He, Daihai
    [J]. IJID REGIONS, 2022, 5 : 177 - 179
  • [6] Impact of Metabolic Acidosis on All-Cause Mortality in Patients With COVID-19
    Kim, Yaerim
    Kwon, Soie
    Lee, Jeonghwan
    Paek, Jin Hyuk
    Park, Woo Yeong
    Jin, Kyubok
    Han, Seungyeup
    Kim, Dong Ki
    Lee, Jung Pyo
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 332 - 333
  • [7] Excess All-Cause Mortality During the COVID-19 Outbreak in Japan
    Yorifuji, Takashi
    Matsumoto, Naomi
    Takao, Soshi
    [J]. JOURNAL OF EPIDEMIOLOGY, 2021, 31 (01) : 90 - 92
  • [8] Predictors of All-Cause Mortality in Heart Transplant Recipients With COVID-19
    De Sirkar, Sovik
    Yu, Mingxi
    [J]. CIRCULATION, 2021, 144
  • [9] Anticoagulants and all-cause mortality among hospitalized COVID-19 patients
    Liang, Caihua
    Zhou, Li
    Doherty, Michael C.
    Gately, Robert V.
    Ogilvie, Rachel P.
    Chomistek, Andrea K.
    Wang, Florence
    Seeger, John D.
    Franklin, Jessica
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 78 - 78
  • [10] IS TRANSAMINITIS AN INDEPENDENT RISK FACTOR FOR ALL-CAUSE MORTALITY IN COVID-19?
    Mughal, Mohsin
    Kaur, Ikwinder P.
    Kakadia, Mili
    Alhashemi, Reem
    Qudah, Hamzah A.
    Azad, Sarah
    Wang, Chang
    Mirza, Hasan M.
    Singh, Harjot
    Priya, Angi
    Eng, Margaret
    [J]. GASTROENTEROLOGY, 2021, 160 (06) : S851 - S851
12345